Clinical Trial

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants

Name: Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants — clinical trial record (NCT07352423)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The primary objective of this study is to evaluate the safety and tolerability of single subcutaneous (SC) doses of ALXN2230 in healthy participants.

Protocol Amendment History 1 change

critical Recruitment opened 2026-04-10

Trial Details

NCT Number	NCT07352423
Lead Sponsor	Alexion Pharmaceuticals, Inc.
Conditions	Healthy Adult Participants
Enrollment	48 participants
Start Date	2026-03-26
Primary Completion	2026-12-23 (estimated)
Study Completion	2026-12-23 (estimated)
Updated on ClinicalTrials.gov	2026-04-09